Open AccessStereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma
Author(s) -
Marie Kate Gurka,
Christine M. Kim,
Aiwu Ruth He,
Aline Charabaty,
Nadim Haddad,
Jenna Turocy,
Lynt B. Johnson,
Patrick G. Jackson,
Louis M. Weiner,
John L. Marshall,
Sean P. Collins,
Michael J. Pishvaian,
Keith Unger
Publication year - 2017
Publication title -
american journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.896
H-Index - 78
eISSN - 1537-453X
pISSN - 0277-3732
DOI - 10.1097/coc.0000000000000118
Subject(s) - medicine , common terminology criteria for adverse events , pancreatic cancer , chemotherapy , adenocarcinoma , radiation therapy , cancer , radiology , surgery , oncology
The role of radiation therapy in the management of unresectable pancreatic cancer is controversial. One concern about concurrent chemoradiation relates to the timing of chemotherapy. In contrast to conventional radiation therapy, stereotactic body radiation therapy (SBRT) delivers high doses in a shorter duration resulting in minimal disruption in chemotherapy. Here, we report our results of patients treated with SBRT and chemotherapy for inoperable pancreatic cancer.